Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01614821
First received: May 17, 2012
Last updated: June 13, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2018
  Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):